Neogen Chemicals Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹5.5K Cr
FY27 and FY28 are expected to see double-digit revenue growth in the base business, especially post the Dahej plant ramp-up. Neogen Chemicals expects steady revenue growth driven by the ramp-up of battery chemicals, including electrolyte and salts production at the Dahej and Pakhajan plants.
From Neogen Chemicals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,230
Market Cap
₹5.5K Cr
P/E Ratio
155.0
How does Neogen Chemicals Ltd rank in Chemicals & Petrochemicals?
Compare Neogen Chemicals Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Neogen Chemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹247 Cr, net profit ₹11 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY27 and FY28 are expected to see double-digit revenue growth in the base business, especially post the Dahej plant ramp-up.
- →Battery chemicals segment projected to generate INR 400-500 crore revenue in FY27, considering limited salt sales from Pakhajan in H2 FY27.
- →Electrolyte revenues are expected to increase in H2 FY27 due to capacity ramps by major customers like Ola, Exide, and Waaree.
- →The Pakhajan salt plant’s full 30,000 MT capacity is targeted to be operational by end of H1 FY27, with gradual ramp-up based on business visibility.
- →By end of 2027, India's battery cell manufacturing capacity expected to reach 40-50 GWh with new and expanding capacities.
- →Salt capacity currently sufficient till FY28; potential need for capacity addition by FY29 depending on international and local demand.
- →The Dahej replacement plant commissioning is on track for Q1 FY27, supporting growth ambitions and future sales expansion.
📈 Profitability & Margins
- →Neogen Chemicals expects steady revenue growth driven by the ramp-up of battery chemicals, including electrolyte and salts production at the Dahej and Pakhajan plants.
- →FY27 battery chemicals revenue is guided at INR 400-500 crore with electrolyte production from Pakhajan starting in H1 FY27 and salts in H2.
- →Base business (organic and inorganic chemicals) is expected to deliver double-digit revenue growth in FY27 and FY28, recovering from fire incident impacts.
- →EBITDA impacted short-term by ramp-up costs, interim toll manufacturing, and higher interest expense related to Dahej plant reconstruction but expected to improve with insurance claim recoveries and operating efficiencies.
- →Promoter equity infusion of INR 150 crore and $20 million from Morita aid in reducing interest burden and support growth initiatives.
- →Full capacity utilization at Dahej (30,000 MT salt) targeted by end H1 FY27 with gradual ramp-up aligned with demand visibility.
- →Insurance claims will partially offset transient costs in FY27 and FY28, supporting profit recovery.
- →Overall, management is confident about growth, margin expansion, and long-term value creation as projects come online.
🏗️ Capital Expenditure Plans
- →Neogen Chemicals is progressing with the Pakhajan greenfield project, targeting:
- → - Electrolyte commercial production in H1 FY27.
- → - Electrolyte salts production in H2 FY27.
- → - Equipment arrival and assembly underway; trial production expected soon.
- →Rebuilding and expansion of the Dahej plant ongoing, with completion and commissioning expected by Q1 FY27 and capacity ramp-up by March 2026.
- →Preferential equity infusion planned from Promoter Group of INR 150 crore by March 2026 to support growth and reduce interest burden.
- →Joint venture with Morita Investment Ltd for LiPF6 salt production, with $20 million investment for 20% stake, expected receipt by Q1 FY27.
- →Planned capacity includes readiness for 30,000 MT salt production and 30 gigawatt-hours electrolyte production by end of H1 FY27.
- →Potential future capacity additions considered around FY29 based on demand growth, with decisions expected by end of FY27/FY28.
💰 Fundraising & Capital Structure
- →Promoter group plans a preferential equity infusion of INR 150 crore, expected before March 2026 or by Q1 FY27, subject to regulatory approvals.
- →Around INR 200 crore equity expected from Morita towards their 20% stake in the JV by end of current quarter or Q1 FY27.
- →Insurance claim recoveries of approximately INR 200 crore expected by March or April 2026.
- →Overall, approximately INR 550 crore (equity + insurance) expected to come in this year or early next year.
- →Debt discussions ongoing with banks to maintain a 70:30 debt-equity ratio for the JV capital; exact debt levels and repayments are being finalized.
- →First principal repayment for Dahej loans expected in Q1 FY28, about one year after SCOD.
- →Some of the funds raised will be used for working capital and capex contributions for ongoing projects.
📋 Order Book & Pipeline
- →Salt business has shown increased interest with many regular and non-regular customers.
- →Majority of requirements for one key customer are complete, with final approval timelines expected by Q1 FY27.
- →Three to four other customers have started sampling and approving, with audits planned between March and May 2026.
- →Dahej site approval expected by June 2026; sales to start progressively from Q2 FY27 onwards.
- →Pakhajan site target approval by September 2026, with trial production starting in H2 FY27 and sales from Q4 FY27.
- →Significant inquiries for lithium salts and intermediates due to regulatory changes and demand growth.
- →Provisional approvals received from multiple global clients with final audits completing in Q1 FY27.
- →Overall, order book and pending approvals are progressing well, enabling ramp-up of supply capacity through 2026 and beyond.
Key Metrics
Frequently Asked Questions
What were Neogen Chemicals Ltd Q3 FY26 results?
FY27 and FY28 are expected to see double-digit revenue growth in the base business, especially post the Dahej plant ramp-up. Neogen Chemicals expects steady revenue growth driven by the ramp-up of battery chemicals, including electrolyte and salts production at the Dahej and Pakhajan plants.
What is Neogen Chemicals Ltd share price analysis?
Neogen Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 155.0 with a market cap of ₹5,511 Cr. Investors should review the full earnings analysis for detailed insights.
Is Neogen Chemicals Ltd planning capital expenditure?
Neogen Chemicals is progressing with the Pakhajan greenfield project, targeting: - Electrolyte commercial production in H1 FY27.
Keep Neogen Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.